Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290244 · ClinicalTrials.gov registry record · Phase 1
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
A Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy), sponsored by Life Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT07290244 is a Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) that is actively recruiting participants, run by Life Biosciences. The registered enrollment target is 18 participants, below the 65-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07290244, a Phase 1 study of Open Angle Glaucoma (OAG) and NAION( Non-arteritic Anterior Ischemic Optic Neuropathy), is actively recruiting participants, sponsored by Life Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes
Conditions Studied
Interventions
- GENETIC ER-100 epigenetic therapy
Study Locations (2)
California
- Global Research Management, Inc. - Glendale
South Carolina
- Charleston Neuroscience Institute - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2032-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07290244
The ClinicalTrials.gov registry entry for NCT07290244 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (72% lower). The listed sponsor is Life Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which ER-100 epigenetic therapy is the first listed.
NCT07290244 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07290244 about?
NCT07290244 is a clinical study titled "Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)". The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 saf...
What is the current status of trial NCT07290244?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-03-02. Estimated completion is 2032-03.
What conditions does trial NCT07290244 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy).
What interventions are being tested in trial NCT07290244?
The interventions under investigation include: ER-100 epigenetic therapy (GENETIC).
Who is sponsoring clinical trial NCT07290244?
This trial is sponsored by Life Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290244 being conducted?
This trial has 2 study locations across California, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
Explore more on PlainTrial
Open Angle Glaucoma (OAG)
All registered trials for this condition
NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.